Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio (QTTB) presented 36-week results from its SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata at EADV 2026. The drug showed clinically meaningful efficacy, with a 35.3% mean reduction in SALT scores. 40% of patients achieved SALT-20 response. The 16-week off-drug period showed durable responses, with 44% maintaining SALT-20. Q32 Bio plans to advance a registration-directed program in 2027.
How this was made
The 30-second read
Why it matters
The data shows a 35.3% mean SALT reduction and durable responses after drug cessation, supporting a registration‑directed program in 2027.
Market read
First public disclosure of Phase 2a results provides a fresh catalyst for QTTB, likely influencing its share price.
What to watch
Potential regulatory hurdles and competition from JAK inhibitors may temper upside.
Background
Q32 Bio (Nasdaq: QTTB) is a clinical‑stage biotech focused on alopecia areata. The company presented Part B data at the EADV Congress 2026.
Ticker impact
Q32 Bio disclosed new Phase 2a trial results for bempikibart, showing meaningful efficacy and durability in alopecia areata patients.
upward pressure as market prices in the encouraging efficacy data
First disclosure of robust 36‑week efficacy and off‑drug durability, a material catalyst for a clinical‑stage biotech.
Market effects
Strengthens the broader autoimmune‑therapy pipeline, may boost peer biotech sentiment.
Limited to US biotech sector.
Modest, confined to specialty pharma investors.
Counterpoint
If durability does not translate to longer‑term outcomes, the rally could be short‑lived.
Key entities
- companyQ32 Bio Inc.
Clinical‑stage biotech developing bempikibart for alopecia areata.